Latest Announcements

Parkinson's Disease, Clinical Trials, Investor Announcement

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"